股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 佰金生命科學控股有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01466 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.02 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.02 | HKD | | 200,000,000 | 本月底法 ...

董事会宣布，继李先生辞任后，独立非执行董事黄兆强先生已获委任为审核委员会主席，自2026年1月 27日起生效。 佰金生命科学(01466)发布公告，李家梁先生由于彼个人原因，故已辞任独立非执行董事，并不再担任 本公司审核委员会主席以及薪酬委员会及提名委员会各自的成员，自2026年1月27日起生效。 ...

董事会宣布，继李先生辞任后，独立非执行董事黄兆强先生已获委任为审核委员会主席，自2026年1月 27日起生效。 智通财经APP讯，佰金生命科学(01466)发布公告，李家梁先生由于彼个人原因，故已辞任独立非执行董 事，并不再担任本公司审核委员会主席以及薪酬委员会及提名委员会各自的成员，自2026年1月27日起 生效。 ...

格隆汇1月27日丨佰金生命科学(01466.HK)公告，李家梁由于彼个人原因，故已辞任独立非执行董事， 并不再担任公司审核委员会主席以及薪酬委员会及提名委员会各自成员，自2026年1月27日起生效。 ...

佰金生命科學控股有限公司董事（「董事」）會（「董事會」）成員列示如下： Baijin Life Science Holdings Limited 佰 金 生 命 科 學 控 股 有 限 公 司 （股份代號： 1466） （於開曼群島註冊成立之有限公司） 董事名單及其角色和職能 執行董事 張詩敏 董鵬 蘇耀耀 非執行董事 朱勇軍 鄭子堅 謝春辰 獨立非執行董事 黃兆強 常春雨 董事會設有三個董事委員會。下表列載各董事委員會的成員資料： | 董事 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 張詩敏 | 不適用 | 成員 | 成員 | | 蘇耀耀 | 不適用 | 成員 | 成員 | | 朱勇軍 | 不適用 | 成員 | 成員 | | 謝春辰 | 不適用 | 不適用 | 成員 | | 黃兆強 | 主席 | 主席 | 主席 | | 常春雨 | 成員 | 成員 | 成員 | 香港，2026年1月27日 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Baijin Life Science Holdings Limited 佰 金 生 命 科 學 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） （股份代號： 1466） (1)獨立非執行董事辭任； (2)未能遵守上市規則； 及 董事會謹此向李先生於在任期間對本公司所作出之寶貴貢獻致以衷心謝意。 未能遵守上市規則 聯交所證券上市規則（「上市規則」）第3.10 (1)及3.10A條規定，上市發行人董事會須 包括至少三名獨立非執行董事，而該等獨立非執行董事須至少佔董事會成員的三 分之一。上市規則第3.21條規定，審核委員會應至少由三名成員組成。上市規則 第3.25條規定，薪酬委員會應保持大多數獨立非執行董事。上市規則第3.27A條規 定，提名委員會應保持大多數獨立非執行董事。李先生辭任後，本公司未能遵守 上市規則第3.10 (1)、 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 佰金生命科學控股有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01466 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.02 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.02 | HKD | | 200,000,000 | 本月底 ...

Baijin Life Science Holdings Limited 佰金生命科學控股有限公司 (Stock Code: 1466) (Incorporated in the Cayman Islands with limited liability) （股份代號： 1466） （於開曼群島註冊成立之有限公司） NOTIFICATION LETTER 通知信函 Date as postmarked Dear Non-registered Holder(s) (Note 1) 佰金生命科學控股有限公司（「本公司」） — 刊發2025年中期報告之通知（「本次公司通訊」） Baijin Life Science Holdings Limited (the "Company") — Notification of publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communica ...

(Stock Code: 1466) （股份代號： 1466） NOTIFICATION LETTER 通知信函 Date as postmarked Baijin Life Science Holdings Limited 佰金生命科學控股有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） Dear Registered Shareholders, Baijin Life Science Holdings Limited (the "Company") — Notification of publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are now available on the Company's website at www.b ...

Revenue and Profitability - Revenue for the six months ended September 30, 2025, was HK$55,145,000, a decrease of 22.4% compared to HK$70,900,000 for the same period in 2024[12] - Gross profit for the same period was HK$8,485,000, down 49.5% from HK$16,805,000 in 2024[12] - Operating profit increased to HK$2,711,000, compared to HK$794,000 in the previous year, marking a significant improvement[12] - Profit for the period was HK$2,517,000, a turnaround from a loss of HK$1,901,000 in 2024[12] - Basic earnings per share for the period was 0.28 HK cents, compared to a loss of 0.92 HK cents per share in the previous year[12] - Total comprehensive income for the period was HK$1,941,000, compared to a loss of HK$5,356,000 in the same period last year[14] Financial Position - As of September 30, 2025, total assets less current liabilities amounted to HK$229,119,000, a decrease from HK$240,451,000 as of March 31, 2025, representing a decline of approximately 4.9%[15] - Current assets totaled HK$221,363,000, slightly down from HK$226,998,000, indicating a decrease of about 2.5%[15] - Net current assets were reported at HK$168,810,000, down from HK$177,275,000, reflecting a decrease of approximately 4.8%[15] - Non-current liabilities decreased to HK$71,301,000 from HK$84,574,000, showing a reduction of about 15.6%[17] - The company's equity attributable to owners increased to HK$140,880,000 from HK$139,283,000, marking a growth of about 1.1%[17] - Cash and cash equivalents rose to HK$57,459,000 from HK$47,773,000, indicating an increase of approximately 20.5%[15] - The company’s total equity reached HK$157,818,000, up from HK$155,877,000, reflecting an increase of about 1.2%[17] Cash Flow and Investments - Net cash used in operating activities was HK$8,121,000, a significant improvement compared to a net cash usage of HK$3,942,000 in the previous year[20] - For the six months ended September 30, 2025, net cash generated from investing activities was HK$220,000, a slight decrease from HK$230,000 in the same period of 2024[21] - The net cash generated from financing activities for the same period was HK$2,026,000, down from HK$13,550,000 in 2024, indicating a significant reduction in financing inflows[21] - The company raised new bank loans amounting to HK$5,995,000 during the period, compared to HK$1,090,000 in the previous year[21] - The company reported a net increase in cash and cash equivalents of HK$10,367,000, compared to HK$9,838,000 in the prior year, representing an increase of approximately 5.4%[21] Segment Performance - The company has three operating segments: jewellery business, skincare business, and strategic investment in real estate financial assets[33] - The jewellery business generated revenue of HK$43,548,000, while the skincare business contributed HK$11,597,000, indicating a significant drop in both segments compared to the previous year[38][41] - Segment profit for the jewellery business was HK$401,000, while the skincare business reported a loss of HK$6,716,000, leading to a total segment loss of HK$6,375,000 for the period[38] - The skincare segment experienced a significant loss, with a segment profit of HK$7,421,000 in the previous year turning into a loss of HK$6,716,000 this year[41] Expenses and Cost Management - Administrative expenses decreased slightly to HK$15,683,000 from HK$16,236,000, showing cost control efforts[12] - Employee benefit expenses for the period were HK$9,209,000, slightly lower than HK$9,368,000 in the previous year[59] - Selling and administrative expenses decreased by approximately HK$1.3 million or 6.7% to approximately HK$18.2 million in HY25, primarily due to reduced revenue[176] Credit and Risk Management - The company reported a provision for expected credit loss of HK$1,953,000, up from HK$142,000 in 2024, reflecting increased caution in financial management[12] - The provision for expected credit losses on trade receivables was HK$54,000, down from HK$362,000 in 2024, indicating improved credit risk management[59] Shareholder and Equity Information - The weighted average number of ordinary shares in issue during the period was 772,391,072, up from 679,328,374 in the previous year[73] - The Group recorded a profit attributable to owners of approximately HK$2.2 million in HY25, compared to a loss of approximately HK$6.2 million in HY24, mainly due to gains on the change in fair value of convertible bonds[177] - A total of 119,863,013 Conversion Shares were issued at a conversion price of HK$0.2628 per share, representing approximately 13.43% of the enlarged issued share capital[116] Strategic Initiatives and Future Plans - The company continues to focus on market expansion and new product development as part of its strategic initiatives[12] - The Group plans to expand its jewellery product offerings to mainland China and other Asian markets, where demand remains strong[139] - The Company aims to maintain operational efficiency and productivity while actively participating in jewellery fairs and events to enhance its customer base[140] - The company entered into a strategic cooperation framework agreement with Youhuan Bio to establish a circRNA technology R&D platform, although the timing and amount of investment have not been determined[165]